PDF(Pubmed)
Abstract：
This study aimed to evaluate two modes of Rigiscan for predicting tadalafil response, and to identify which Rigiscan variables are the most efficient at making these predictions.
All patients received at least two rounds of nocturnal penile tumescence and rigidity (NPTR) testing and/or audiovisual sexual stimulation (AVSS), then completed the International Index of Erectile Function-5 (IIEF-5) questionnaire, followed by oral 5 mg tadalafil daily for 4 weeks. After a 4-week washout period, all respondents underwent an the IIEF-5 questionnaire again. ED patients were then categorized into tadalafil responders and tadalafil non-responders, who were then further divided into cured patients and uncured patients.
When predicting tadalafil responders, the area under the curve (AUC) of NPTR was superior to that of AVSS (0.68~0.84 VS 0.69~0.73), and the predicted optimal cut-off values were DOEE60≥17.75 min in NPTR, compared to other parameters regardless of AVSS or NPTR (P<0.05). When predicting which patients would be cured, the AUC of AVSS was superior to NPTR parameters (0.77~0.81 vs 0.61~0.76), and the determined best diagnostic cut-off values were DOEE≥4.125min in AVSS, compared to other parameters regardless of AVSS or NPTR (P < 0.05).
Rigiscan was able to predict the efficacy of daily tadalafil accurately and efficiently. Its diagnostic value was at maximum when DOEE60 ≥17.75 min of NPTR in tadalafil responders and DOEE ≥ 4.125 min of AVSS in cured patients.
All patients received at least two rounds of nocturnal penile tumescence and rigidity (NPTR) testing and/or audiovisual sexual stimulation (AVSS), then completed the International Index of Erectile Function-5 (IIEF-5) questionnaire, followed by oral 5 mg tadalafil daily for 4 weeks. After a 4-week washout period, all respondents underwent an the IIEF-5 questionnaire again. ED patients were then categorized into tadalafil responders and tadalafil non-responders, who were then further divided into cured patients and uncured patients.
When predicting tadalafil responders, the area under the curve (AUC) of NPTR was superior to that of AVSS (0.68~0.84 VS 0.69~0.73), and the predicted optimal cut-off values were DOEE60≥17.75 min in NPTR, compared to other parameters regardless of AVSS or NPTR (P<0.05). When predicting which patients would be cured, the AUC of AVSS was superior to NPTR parameters (0.77~0.81 vs 0.61~0.76), and the determined best diagnostic cut-off values were DOEE≥4.125min in AVSS, compared to other parameters regardless of AVSS or NPTR (P < 0.05).
Rigiscan was able to predict the efficacy of daily tadalafil accurately and efficiently. Its diagnostic value was at maximum when DOEE60 ≥17.75 min of NPTR in tadalafil responders and DOEE ≥ 4.125 min of AVSS in cured patients.
摘要：
本研究旨在评估Rigiscan预测他达拉非反应的两种模式，并确定哪些Rigiscan变量在做出这些预测时最有效。
所有患者接受至少两轮夜间阴茎肿胀和僵硬（NPTR）测试和/或视听性刺激（AVSS）。然后完成了国际勃起功能指数-5(IIEF-5)问卷，随后口服5mg他达拉非，每日4周。经过4周的冲洗期，所有受访者再次接受了IIEF-5问卷.然后将ED患者分为他达拉非应答者和他达拉非非应答者，然后进一步分为治愈患者和未治愈患者。
在预测他达拉非反应者时，NPTR的曲线下面积（AUC）优于AVSS（0.68〜0.84VS0.69〜0.73），在NPTR中，预测的最佳截止值为DOEE60≥17.75min，与其他参数相比，无论AVSS或NPTR（P<0.05）。当预测哪些患者会被治愈时，AVSS的AUC优于NPTR参数（0.77〜0.81vs0.61〜0.76），在AVSS中确定的最佳诊断临界值为DOEE≥4.125min，与其他参数相比，无论AVSS或NPTR（P<0.05）。
Rigiscan能够准确有效地预测每日他达拉非的疗效。当他达拉非应答者的DOEE60≥17.75minNPTR和治愈患者的DOEE≥4.125minAVSS时，其诊断价值最大。
所有患者接受至少两轮夜间阴茎肿胀和僵硬（NPTR）测试和/或视听性刺激（AVSS）。然后完成了国际勃起功能指数-5(IIEF-5)问卷，随后口服5mg他达拉非，每日4周。经过4周的冲洗期，所有受访者再次接受了IIEF-5问卷.然后将ED患者分为他达拉非应答者和他达拉非非应答者，然后进一步分为治愈患者和未治愈患者。
在预测他达拉非反应者时，NPTR的曲线下面积（AUC）优于AVSS（0.68〜0.84VS0.69〜0.73），在NPTR中，预测的最佳截止值为DOEE60≥17.75min，与其他参数相比，无论AVSS或NPTR（P<0.05）。当预测哪些患者会被治愈时，AVSS的AUC优于NPTR参数（0.77〜0.81vs0.61〜0.76），在AVSS中确定的最佳诊断临界值为DOEE≥4.125min，与其他参数相比，无论AVSS或NPTR（P<0.05）。
Rigiscan能够准确有效地预测每日他达拉非的疗效。当他达拉非应答者的DOEE60≥17.75minNPTR和治愈患者的DOEE≥4.125minAVSS时，其诊断价值最大。
